Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer: A Phase 2 Clinical Trial

IMPORTANCE: Stereotactic ablative radiotherapy (SABR) is a standard treatment option in patients with medically inoperable early-stage non–small cell lung cancer (NSCLC), yet the pathologic complete response (pCR) rate after SABR is unknown. Neoadjuvant SABR in patients with cancer who are fit for r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Palma, David A., Nguyen, Timothy K., Louie, Alexander V., Malthaner, Richard, Fortin, Dalilah, Rodrigues, George B., Yaremko, Brian, Laba, Joanna, Kwan, Keith, Gaede, Stewart, Lee, Ting, Ward, Aaron, Warner, Andrew, Inculet, Richard
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512269/
https://ncbi.nlm.nih.gov/pubmed/30789648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.6993
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars